Benitec Biopharma Future Growth
Future criteria checks 0/6
Benitec Biopharma is forecast to grow earnings and revenue by 23.2% and 74.7% per annum respectively while EPS is expected to grow by 20% per annum.
Key information
23.2%
Earnings growth rate
20.0%
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | 74.7% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 16 Dec 2024 |
Recent future growth updates
No updates
Recent updates
Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth
Oct 02Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable
Nov 30Benitec Biopharma prices of $18M securities offering
Sep 13Benitec GAAP EPS of -$2.23, revenue of $0.07M
Sep 02We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate
Jan 13We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully
Sep 30Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?
May 12Benitec Bio secures $13M capital via equity offering
Apr 28Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?
Jan 27How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?
Dec 02Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2027 | N/A | -61 | -10 | N/A | 5 |
6/30/2026 | N/A | -43 | -20 | N/A | 6 |
6/30/2025 | N/A | -31 | -36 | -24 | 7 |
9/30/2024 | N/A | -21 | -20 | -19 | N/A |
6/30/2024 | N/A | -22 | -20 | -19 | N/A |
3/31/2024 | 0 | -22 | -20 | -20 | N/A |
12/31/2023 | 0 | -22 | -18 | -18 | N/A |
9/30/2023 | 0 | -21 | -19 | -19 | N/A |
6/30/2023 | 0 | -20 | -18 | -18 | N/A |
3/31/2023 | 0 | -20 | -19 | -19 | N/A |
12/31/2022 | 0 | -19 | -18 | -18 | N/A |
9/30/2022 | 0 | -18 | -16 | -16 | N/A |
6/30/2022 | 0 | -18 | -16 | -16 | N/A |
3/31/2022 | 0 | -17 | -16 | -16 | N/A |
12/31/2021 | 0 | -18 | -15 | -15 | N/A |
9/30/2021 | 0 | -16 | -15 | -15 | N/A |
6/30/2021 | 0 | -14 | -13 | -13 | N/A |
3/31/2021 | 0 | -13 | -11 | -11 | N/A |
12/31/2020 | 0 | -11 | -10 | -10 | N/A |
9/30/2020 | 0 | -10 | -10 | -9 | N/A |
6/30/2020 | 0 | -8 | -8 | -8 | N/A |
3/31/2020 | 1 | -7 | -6 | -6 | N/A |
12/31/2019 | 1 | -6 | N/A | N/A | N/A |
9/30/2019 | 7 | -2 | 2 | 2 | N/A |
6/30/2019 | 12 | 3 | 4 | 5 | N/A |
3/31/2019 | 12 | 2 | 4 | 4 | N/A |
12/31/2018 | 12 | 2 | N/A | N/A | N/A |
9/30/2018 | 8 | -3 | -3 | -3 | N/A |
6/30/2018 | 3 | -9 | N/A | -7 | N/A |
3/31/2018 | 4 | -9 | N/A | -7 | N/A |
12/31/2017 | 6 | -7 | N/A | -5 | N/A |
9/30/2017 | 5 | -7 | N/A | -5 | N/A |
6/30/2017 | 9 | -4 | N/A | -6 | N/A |
3/31/2017 | 7 | -7 | N/A | -6 | N/A |
12/31/2016 | 7 | -8 | N/A | -10 | N/A |
9/30/2016 | 7 | -12 | N/A | -13 | N/A |
6/30/2016 | 3 | -18 | N/A | -15 | N/A |
3/31/2016 | 3 | -18 | N/A | -17 | N/A |
12/31/2015 | 2 | -16 | N/A | -14 | N/A |
9/30/2015 | 2 | -12 | N/A | -10 | N/A |
6/30/2015 | 3 | -9 | N/A | -7 | N/A |
3/31/2015 | 3 | -6 | N/A | -5 | N/A |
12/31/2014 | 1 | -7 | N/A | -7 | N/A |
9/30/2014 | 1 | -7 | N/A | -8 | N/A |
6/30/2014 | 1 | -7 | N/A | -9 | N/A |
3/31/2014 | 1 | -5 | N/A | -8 | N/A |
12/31/2013 | 1 | -3 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BNTC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BNTC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BNTC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BNTC is forecast to have no revenue next year.
High Growth Revenue: BNTC is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BNTC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 13:28 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Benitec Biopharma Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Brian Skorney | Baird |
Debjit Chattopadhyay | Guggenheim Securities, LLC |
Raghuram Selvaraju | H.C. Wainwright & Co. |